Botulinum Neurotoxin in Chronic Pain Management

Pain Practice

Volumn 4, Issue , 2004, Pages S68-S72

  Raj, P Prithvi ^a  

^a World Institute of Pain   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BOTULINUM TOXIN A; BOTULINUM TOXIN B; CAPSAICIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ANALGESIA; ANTINOCICEPTION; ARTICLE; CERVICAL DYSTONIA; CHRONIC PAIN; DRUG EFFICACY; DRUG POTENCY; DYSPHAGIA; HEADACHE; HUMAN; INJECTION SITE CONTUSION; INJECTION SITE REACTION; LOW BACK PAIN; MUSCLE WEAKNESS; NECK PAIN; NEUROANATOMY; NONHUMAN; PTOSIS; QUALITY OF LIFE; SHOULDER PAIN;

EID: 18844403651     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2004.04016.x     Document Type: Article

References (26)

1. Katz N. The impact of pain management on quality of life. J Pain Symptom Manage. 2002;24(suppl 1):S38-S47.
2. Sternbach RA. Pain and "hassles" in the United States: findings of the Nuprin pain report. Pain. 1986;27: 69-80.
3. Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pogoda JM. Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg. 2000;123: 669-676.
4. Tsui JKC, Eisen A, Stoessl AJ, Calne S, Calne DB. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet. 1986;2: 245-247.
5. Arezzo JC. Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain. 2002;18(6 suppl):S125-S132.
6. Ishikawa H, Mitsui Y, Yoshitomi T, et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol. 2000;44: 106-109.
7. Welch MJ, Purkiss JR, Foster KA. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon. 2000;38: 245-258.
8. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol. 1993;113: 400-404.
9. Giladi N. The mechanism of action of Botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neurol Sci. 1997;152: 132-135.
10. Cui M, Chaddock JA, Rubino J, et al. Retargeted clostridial endopeptidase: antinociceptive activity in preclinical models of pain [abstract 21]. Naunyn Schmiedebergs Arch Pharmacol. 2002;365(suppl 2):R16.
11. Relja MA, Klepac N. Botulinum toxin type A as prophylactic treatment in chronic tension-type headache: long-term follow-up study [abstract P05.090]. Neurology. 2001;56(suppl 3):A349-A350.
12. Royal MA. The use of botulinum toxins in the management of pain and headache. Pain Practice. 2001;1: 215-235.
13. Relja M. Treatment of tension-type headache by local injection of botulinum toxin. Eur J Neurol. 1997;4(suppl 2):S71-S73.
14. Relja MA, Korsic M. Treatment of tension-type headache by injections of botulinum-toxin type A: double-blind placebo-controlled study [abstract P03.035]. Neurology. 1999;52(suppl 2):A203.
15. Barrientos N, Chana P. Efficacy and safety of botulinum toxin type A (Botox) in the prophylactic treatment of migraine [abstract S106]. Headache. 2002;42: 452.
16. Bovim G, Schrader H, Sand T. Neck pain in the general population. Spine. 1994;19: 1307-1309.
17. Cote P, Cassidy JD, Carroll L. The Saskatchewan Health and Back Pain Survey. The prevalence of neck pain and related disability in Saskatchewan adults. Spine. 1998;23: 1689-1698.
18. Makela M, Heliovaara M, Sievers K, Impivaara O, Knekt P, Aromaa A. Prevalence, determinants, and consequences of chronic neck pain in Finland. Am J Epidemiol. 1991;134: 1356-1367.
19. Argoff CE. Pharmacologic management of chronic pain. J Am Osteopath Assoc. 2002;102(suppl 3):S21-S27.
20. Difazio M, Jabbari B. A focused review of the use of botulinum toxins for low back pain. Clin J Pain. 2002;18(6 suppl):S155-S162.
21. Critchfield J. Considering the immune response to botulinum toxin. Clin J Pain. 2002;18(6 suppl):S133-S141.
22. ® Cervical Dystonia Prospective Study Group. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia. J Neurol. 2002;249: 57-63.
23. Setler PE. Pharmacology of botulinum toxin type B. Eur J Neurol. 2001;8(suppl 4):9-12.
24. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53: 1439-1446.
25. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53: 1431-1438.
26. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003;60: 1186-1188.